• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of biochemjBJ Latest papers and much more!
Biochem J. Jun 15, 2001; 356(Pt 3): 899–906.
PMCID: PMC1221919

Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.


Although MK886 was originally identified as an inhibitor of 5-lipoxygenase activating protein (FLAP), recent data demonstrate that this activity does not underlie its ability to induce apoptosis [Datta, Biswal and Kehrer (1999) Biochem. J. 340, 371--375]. Since FLAP is a fatty-acid binding protein, it is conceivable that MK886 may affect other such proteins. A family of nuclear receptors that are activated by fatty acids and their metabolites, the peroxisome-proliferator-activated receptors (PPARs), have been implicated in apoptosis and may represent a target for MK886. The ability of MK886 to inhibit PPAR-alpha, -beta and -gamma activity was assessed using reporter assay systems (peroxisome-proliferator response element--luciferase). Using a transient transfection system in monkey kidney fibroblast CV-1 cells, mouse keratinocyte 308 cells and human lung adenocarcinoma A549 cells, 10--20 microM MK886 inhibited Wy14,643 activation of PPAR alpha by approximately 80%. Similar inhibition of PPAR alpha by MK886 was observed with a stable transfection reporter system in CV-1 cells. Only minimal inhibitory effects were seen on PPAR beta and PPAR gamma. MK886 inhibited PPAR alpha by a non-competitive mechanism as shown by its effects on the binding of arachidonic acid to PPAR alpha protein, and a dose-response study using a transient transfection reporter assay in COS-1 cells. An assay assessing PPAR ligand-receptor interactions showed that MK886 prevents the conformational change necessary for active-complex formation. The expression of keratin-1, a protein encoded by a PPAR alpha-responsive gene, was reduced by MK886 in a culture of mouse primary keratinocytes, suggesting that PPAR inhibition has functional consequences in normal cells. Although Jurkat cells express all PPAR isoforms, various PPAR alpha and PPAR gamma agonists were unable to prevent MK886-induced apoptosis. This is consistent with MK886 functioning as a non-competitive inhibitor of PPAR alpha, but may also indicate that PPAR alpha is not directly involved in MK886-induced apoptosis. Although numerous PPAR activators have been identified, the results show that MK886 can inhibit PPAR alpha, making it the first compound identified to have such an effect.

Full Text

The Full Text of this article is available as a PDF (191K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5241–5246. [PMC free article] [PubMed]
  • Anderson KM, Levin J, Jajeh A, Seed T, Harris JE. Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase. Prostaglandins Leukot Essent Fatty Acids. 1993 Apr;48(4):323–326. [PubMed]
  • Anderson KM, Seed T, Plate JM, Jajeh A, Meng J, Harris JE. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk Res. 1995 Nov;19(11):789–801. [PubMed]
  • Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martínez A, Mulshine JL. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996 Feb 1;97(3):806–813. [PMC free article] [PubMed]
  • Buyn T, Dudeja P, Harris JE, Ou D, Seed T, Sawlani D, Meng J, Bonomi P, Anderson KM. A 5-lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell death. Prostaglandins Leukot Essent Fatty Acids. 1997 Jan;56(1):69–77. [PubMed]
  • Vickers PJ. 5-Lipoxygenase-activating protein (FLAP). J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):185–194. [PubMed]
  • Anderson KM, Seed T, Jajeh A, Dudeja P, Byun T, Meng J, Ou D, Bonomi P, Harris JE. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 1996 Sep-Oct;16(5A):2589–2599. [PubMed]
  • Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13182–13187. [PMC free article] [PubMed]
  • Datta K, Biswal SS, Xu J, Towndrow KM, Feng X, Kehrer JP. A relationship between 5-lipoxygenase-activating protein and bcl-xL expression in murine pro-B lymphocytic FL5.12 cells. J Biol Chem. 1998 Oct 23;273(43):28163–28169. [PubMed]
  • Datta K, Biswal SS, Kehrer JP. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J. 1999 Jun 1;340(Pt 2):371–375. [PMC free article] [PubMed]
  • Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 1993 Mar 8;318(3):277–281. [PubMed]
  • Sandstrom PA, Pardi D, Tebbey PW, Dudek RW, Terrian DM, Folks TM, Buttke TM. Lipid hydroperoxide-induced apoptosis: lack of inhibition by Bcl-2 over-expression. FEBS Lett. 1995 May 22;365(1):66–70. [PubMed]
  • Ramakrishnan N, Kalinich JF, McClain DE. Ebselen inhibition of apoptosis by reduction of peroxides. Biochem Pharmacol. 1996 Jun 14;51(11):1443–1451. [PubMed]
  • Sandstrom PA, Tebbey PW, Van Cleave S, Buttke TM. Lipid hydroperoxides induce apoptosis in T cells displaying a HIV-associated glutathione peroxidase deficiency. J Biol Chem. 1994 Jan 14;269(2):798–801. [PubMed]
  • Köller M, Wachtler P, Dávid A, Muhr G, König W. Arachidonic acid induces DNA-fragmentation in human polymorphonuclear neutrophil granulocytes. Inflammation. 1997 Oct;21(5):463–474. [PubMed]
  • Surette ME, Fonteh AN, Bernatchez C, Chilton FH. Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis. 1999 May;20(5):757–763. [PubMed]
  • Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):681–686. [PMC free article] [PubMed]
  • Vanden Heuvel JP. Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J Nutr. 1999 Feb;129(2S):575S–580S. [PubMed]
  • Roberts RA. Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Ann N Y Acad Sci. 1996 Dec 27;804:588–611. [PubMed]
  • Perrone CE, Shao L, Williams GM. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol. 1998 Jun;150(2):277–286. [PubMed]
  • Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis. 1998 Jan;19(1):43–48. [PubMed]
  • Hasmall SC, James NH, Macdonald N, Gonzalez FJ, Peters JM, Roberts RA. Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha. Mutat Res. 2000 Mar 17;448(2):193–200. [PubMed]
  • Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998 Oct 2;273(40):25573–25580. [PubMed]
  • Goll V, Viollon-Abadie C, Nicod L, Richert L. Peroxisome proliferators induce apoptosis and decrease DNA synthesis in hepatoma cell lines. Hum Exp Toxicol. 2000 Mar;19(3):193–202. [PubMed]
  • Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, Brown EM. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res. 2000 Jul 1;61(1):67–74. [PubMed]
  • Kulesz-Martin M, Kilkenny AE, Holbrook KA, Digernes V, Yuspa SH. Properties of carcinogen altered mouse epidermal cells resistant to calcium-induced terminal differentiation. Carcinogenesis. 1983 Nov;4(11):1367–1377. [PubMed]
  • Conti CJ, Fries JW, Viaje A, Miller DR, Morris R, Slaga TJ. In vivo behavior of murine epidermal cell lines derived from initiated and noninitiated skin. Cancer Res. 1988 Jan 15;48(2):435–439. [PubMed]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed]
  • Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992 Aug 27;358(6389):771–774. [PubMed]
  • Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355–7359. [PMC free article] [PubMed]
  • Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997 Jun;11(6):779–791. [PubMed]
  • Devchand PR, Hihi AK, Perroud M, Schleuning WD, Spiegelman BM, Wahli W. Chemical probes that differentially modulate peroxisome proliferator-activated receptor alpha and BLTR, nuclear and cell surface receptors for leukotriene B(4). J Biol Chem. 1999 Aug 13;274(33):23341–23348. [PubMed]
  • Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953–12956. [PubMed]
  • Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1992 Jun;70(6):799–807. [PubMed]
  • Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res. 2000 Mar 17;448(2):121–138. [PubMed]
  • Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102–6106. [PMC free article] [PubMed]
  • He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999 Oct 29;99(3):335–345. [PMC free article] [PubMed]
  • DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Ventre J, Wu MS, Peters JM, Gonzalez FJ, et al. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Mol Pharmacol. 2000 Sep;58(3):470–476. [PubMed]
  • Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000 Apr 13;270(2):400–405. [PubMed]
  • Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem. 1999 Jun 11;274(24):17042–17048. [PubMed]
  • Altiok S, Xu M, Spiegelman BM. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997 Aug 1;11(15):1987–1998. [PMC free article] [PubMed]
  • Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS, Mitchell MD. 15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun. 1999 Sep 7;262(3):579–585. [PubMed]
  • Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998 Sep;4(9):1053–1057. [PubMed]
  • Glatz JF, Vork MM, Cistola DP, van der Vusse GJ. Cytoplasmic fatty acid binding protein: significance for intracellular transport of fatty acids and putative role on signal transduction pathways. Prostaglandins Leukot Essent Fatty Acids. 1993 Jan;48(1):33–41. [PubMed]
  • Glatz JF, Börchers T, Spener F, van der Vusse GJ. Fatty acids in cell signalling: modulation by lipid binding proteins. Prostaglandins Leukot Essent Fatty Acids. 1995 Feb-Mar;52(2-3):121–127. [PubMed]
  • Glatz JF, van Nieuwenhoven FA, Luiken JJ, Schaap FG, van der Vusse GJ. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1997 Oct;57(4-5):373–378. [PubMed]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...